Brind.

Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.

3 reports, 1 independent Updated Jun 23
Gone quiet
Reports
3
Developments
5
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.

Who's involved

What this event is mainly about
PfizerAstraZenecaMerck

How it developed

Newest first. Tap a step to see who reported it.
  1. AstraZeneca's drug was tested in collaboration with Pfizer's drug.Sub-event
  2. Pfizer acquired Biohaven Pharmaceuticals, Seagen, and Arena Pharmaceuticals in transactions dating back to 2022.Sub-event
  3. Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.Sub-event
  4. Certara and Merck announced an expansion of their clinical technology collaboration, which began on July 8, 2025.Sub-event
  5. Pfizer strengthens oncology position via Seagen acquisition; AZ forms new partnerships with Daiichi and Merck.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped